[Venous thrombosis and thrombophilic management of prevention and therapy].
Cardiovascular disease, to which venous thrombosis and pulmonary embolism contribute a major part, are the leading cause of death in industrialized countries. Thrombosis is caused by temporary risk factors or by thrombophilia. Increasing knowledge concerning the pathophysiology of thrombosis and new diagnostic tools allow a thrombotic risk assessment. In this paper thrombotic risk factors will be discussed with respect to their significance and diagnosis as well as methods of prophylaxis and treatment for patients at risk for or with diagnosed thrombosis. Furthermore, currently available as well as new anticoagulants (pentasaccharide, melagatran) will be discussed and their potential for patient-oriented and cost-efficient prophylaxis and treatment of thromboembolic complications outlined.
Ruef
J
J
Medizinische Klinik III/Kardiologie, Angiologie, Pulmologie, Gerinnungsambulanz und Thrombophiliesprechstunde, Universität Heidelberg, Bergheimer Str. 58, 69115 Heidelberg. johannes_ruef@med.uni-heidelberg.de
Katus
H A
HA
D017984:Enoxaparin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D012307:Risk Factors; D019851:Thrombophilia / Q000517:prevention & control / Q000628:therapy*; D000078222:Tinzaparin; D020246:Venous Thrombosis / Q000151:congenital / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*
D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin